Cell Therapy News

Clinicians who treat blood cancers often disagree whether chimeric antigen receptor T-cell therapies are a potential replacement for hematopoietic stem cell transplant.

CRISPR may be the most notable name in the world of gene editing, but it’s not the only option.

The FDA in February approved lisocabtagene maraleucel — a chimeric antigen receptor T cell therapy — for treatment of relapsed or refractory diffuse large B-cell lymphoma.

The FDA granted fast track designation to DA01, a stem cell-based therapy, for the treatment of advanced Parkinson’s disease.

CD19-directed chimeric antigen receptor T-cell therapies have produced unprecedented response rates among patients with advanced hematologic malignancies, yet many patients who respond to this therapy experience disease relapse.

Navneet Majhail, MD, MS, FASTCT, has been appointed deputy physician-in-chief of blood cancers for Sarah Cannon Transplant and Cellular Therapy Network.

Peter Abdelmessieh, DO, MSc, has joined the department of bone marrow transplant and cellular therapies at Fox Chase Cancer Center.

The FDA granted orphan drug designation to ALS001, an autologous, expanded T-cell therapy under development by Coya Therapeutics for treating ALS, according to a press release.

Sarah K. Tasian, MD, has been appointed chief of the section of hematologic malignancies within the division of oncology at Children’s Hospital of Philadelphia.

Moffitt Cancer Center in Tampa has been one of the early leaders in cellular therapies for cancer treatment.